Venus Remedies Limited has received marketing approval from the Philippines, the second largest ASEAN market, for six key chemotherapy drugs. Venus Remedies has secured marketing authorization for bortezomib cisplatin, doxorubicin, docetaxel, flurouracil and paclitaxel from the Philippines, thus making it a significant market for the company from the ASEAN region. With this, Venus Remedies has secured 525 marketing approvals for its oncology products across 76 Countries.

Meanwhile, executing its expansion plans in the ASEAN region the company's oncology wing has also secured marketing approval from Myanmar for the chemotherapy drug oxaliplatin. Three months after Venus Remedies had got marketing authorization from Malaysia, one of the largest pharmaceutical markets in Southeast Asia, for another chemotherapy medication, pemetrexed, the company has now secured a product registration for a different dosage of the same drug. Venus Remedies' oncology products are widely used in many big chemotherapy centres in Malaysia.

like Onco Life.